MicroRNAs and prostate cancer: From preclinical research to translational oncology

AbstractThe management of prostate cancer patients is rapidly changing. The extended survival seen in randomized phase III trials with new molecules has significantly enriched the therapeutic armamentarium, and ongoing clinical trials are assessing whether the integration of these active drugs withi